Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Completed 8Terminated 5Recruiting 5Withdrawn 1Unknown 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2FED 1

Study Type

Interventional 3Observational 2

Sponsor

Cancer Type

Genitourinary 5

Conditions

Prostatic Neoplasms 36Prostatic Neoplasms, Castration-Resistant 5Neoplasm Metastasis 5Metastatic Castration-Resistant Prostate Cancer 4Neoplasms 3Small Cell Lung Carcinoma 2Prostatic Diseases 2Prostate Adenocarcinoma 2Adenocarcinoma 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Sleep Initiation and Maintenance Disorders 1Recurrence 1Prostate Cancer Metastatic 1Pathologic Complete Response 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasm, Residual 1Neoadjuvant Therapy 1Metastatic Hormone-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Metastatic Castrate-Resistant Prostate Cancer 1Mesothelioma, Malignant 1Melanoma 1

Interventions

pembrolizumab 49Specimen Handling 29Magnetic Resonance Spectroscopy 25Biopsy 25Radiosurgery 17Gemcitabine 17Nivolumab 16Cyclophosphamide 14Cisplatin 14Paclitaxel 13Carboplatin 13Bevacizumab 13Leucovorin 11Irinotecan 11Fluorouracil 11Drug Therapy 11Taxes 10Radiotherapy 10Oxaliplatin 10Capecitabine 10trastuzumab deruxtecan 9fludarabine 9cemiplimab 8Doxorubicin 8Cetuximab 8abemaciclib 7Trastuzumab 7Pemetrexed 7Fulvestrant 7Docetaxel 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Neoplasm Metastasis × enzalutamide × Clear all
NCT06863272 2026-05-29

IDeate-Prostate02

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
360 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant

NCT04787744 2026-04-08

VA STARPORT

VA Office of Research and Development

Phase 2/3 Recruiting
464 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT04729114 2026-02-04

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Astellas Pharma Inc

Phase 1 Recruiting
174 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT06652607 2025-03-12

PSA-DEEP02

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Recruiting
152 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT06473259 2024-06-25

ECHOS

Santa Chiara Hospital

Recruiting
3,000 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡